Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 73INDUSTRY 59NIH 11OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Advanced Rare Tumours 1

Interventions

Gemcitabine 3Carboplatin 3cabozantinib 2Magnetic Resonance Spectroscopy 2Interferon-alpha 2Granulocyte Colony-Stimulating Factor 2Gene Expression Profiling 2Filgrastim 2Etoposide 2Doxorubicin 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1siltuximab 1pembrolizumab 1peginterferon alfa-2b 1pegfilgrastim 1pazopanib 1lenvatinib 1fludarabine 1aldesleukin 1Vincristine 1Thrombopoietin 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Renal Cell × Sunitinib × Clear all
NCT01164228 2023-06-15

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

Eastern Cooperative Oncology Group

Phase 2 Completed
87 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡